Predictive Impact of PD-L1 expression for anti-tumor activity of osimertinib in patients with T790M mutated non-small cell lung cancer - Predictive Impact of PD-L1 expression for osimertinib

2nd division, Department of internal medicine, Hamamatsu University School of Medicine0 个研究点目标入组 46 人开始时间: 2017年4月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Previously treated with osimertinib 2. Previously treated with PD-1/PD-L1 antibody 3. Receiving rifampicin or carbamazepine or St. John's wort and cannot stop. 4. Presence of other active malignancies 5. Pregnant, or have possibility of pregnant, or breast feeding 6. Presence of or have previous history of interstitial lung disease 7. With severe complication which could interfere 8. With active infection including HIV or HBV 9. Unable to have medication per oral 10. Have a history of hypersensitivity with osimeritinib 11. Considered as inadequate for enrollment by primary physician.

发起方

2nd division, Department of internal medicine, Hamamatsu University School of Medicine